<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03203369</url>
  </required_header>
  <id_info>
    <org_study_id>UCART123_02</org_study_id>
    <nct_id>NCT03203369</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN</brief_title>
  <acronym>ABC123</acronym>
  <official_title>Phase 1, Open-label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of a Single Dose of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cellectis S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cellectis S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1 dose-finding study of Universal Chimeric Antigen Receptor T-cells targeting cluster
      of differentiation (CD) 123 (UCART123) administered intravenously to patients with relapsed
      or refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), followed by a dose
      expansion phase in relapsed or refractory BPDCN patients or newly diagnosed BPDCN patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The trial was discontinued due to sponsor's decision and not a consequence of any safety
    concern.
  </why_stopped>
  <start_date type="Actual">June 28, 2017</start_date>
  <completion_date type="Actual">June 27, 2019</completion_date>
  <primary_completion_date type="Actual">June 27, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence, nature, and severity of adverse events and serious adverse events</measure>
    <time_frame>Through day 84</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)</condition>
  <arm_group>
    <arm_group_label>Part 1: Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single intravenous administration of UCART123. Dose escalation in Part 1 will include 3 doses ranging from 6.25 x 10^5 cells/kg to 6.25 x 10^6 cells/kg and continue until the Recommended Phase 2 Dose (RP2D) is identified.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single intravenous administration of UCART123 at the RP2D. 2 Cohorts: Patients with Relapsed/Refractory BPDCN and Newly Diagnosed BPDCN.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UCART123</intervention_name>
    <description>Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor given as a single dose following a lymphodepleting regimen.</description>
    <arm_group_label>Part 1: Dose Escalation</arm_group_label>
    <arm_group_label>Part 2: Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Patients with a diagnosis BPDCN according to World Health Organization (WHO)
             classification confirmed by hematopathology;

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ioana Kloos, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cellectis S.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 14, 2017</study_first_submitted>
  <study_first_submitted_qc>June 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2017</study_first_posted>
  <last_update_submitted>July 29, 2019</last_update_submitted>
  <last_update_submitted_qc>July 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blastic plasmacytoid dendritic cell neoplasm</keyword>
  <keyword>Natural Killer (NK) cell blastic lymphoma</keyword>
  <keyword>Hematologic malignancies</keyword>
  <keyword>Cluster of differentiation (CD) CD4+CD56+ hematodermic tumor</keyword>
  <keyword>Acute leukemia and myeloid neoplasms</keyword>
  <keyword>Chimeric Antigen Receptor T-cell (CAR-T) therapy</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Cluster of differentiation 4 (CD4)</keyword>
  <keyword>Cluster of differentiation 56 (CD56)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

